Blueprint Medicines Corporation
BPMC
$89.65
$3.714.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 146.37M | 128.18M | 138.16M | 96.12M | 71.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.37M | 128.18M | 138.16M | 96.12M | 71.96M |
| Cost of Revenue | 7.45M | 1.93M | 7.59M | 3.19M | 215.00K |
| Gross Profit | 138.92M | 126.25M | 130.56M | 92.93M | 71.74M |
| SG&A Expenses | 96.45M | 89.93M | 89.34M | 83.56M | 79.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.57M | 177.16M | 181.20M | 174.94M | 177.07M |
| Operating Income | -41.20M | -48.97M | -43.05M | -78.82M | -105.11M |
| Income Before Tax | -49.28M | -56.00M | -49.89M | 89.32M | -110.86M |
| Income Tax Expenses | 672.00K | 273.00K | 102.00K | 180.00K | 61.00K |
| Earnings from Continuing Operations | -49.96M | -56.28M | -49.99M | 89.14M | -110.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.96M | -56.28M | -49.99M | 89.14M | -110.92M |
| EBIT | -41.20M | -48.97M | -43.05M | -78.82M | -105.11M |
| EBITDA | -37.20M | -45.11M | -39.43M | -74.01M | -103.58M |
| EPS Basic | -0.79 | -0.89 | -0.80 | 1.45 | -1.82 |
| Normalized Basic EPS | -0.71 | -0.55 | -0.50 | -0.86 | -1.32 |
| EPS Diluted | -0.79 | -0.89 | -0.80 | 1.40 | -1.82 |
| Normalized Diluted EPS | -0.71 | -0.55 | -0.50 | -0.83 | -1.32 |
| Average Basic Shares Outstanding | 63.60M | 63.38M | 62.85M | 61.58M | 60.89M |
| Average Diluted Shares Outstanding | 63.60M | 63.38M | 62.85M | 63.80M | 60.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
